Skip to main content

Table 2 Frequency of cancer in children served by the IMSS and residing in ten jurisdictions of the Mexican Republic during the periods 1996–2002 and 1998–2000

From: Incidence of cancer in children residing in ten jurisdictions of the Mexican Republic: importance of the Cancer registry (a population-based study)

Diagnostic Group 1996–2002 1998–2000
  CHIS MC GRO MS MOR JAL NL PUE VER YUC Overall
  n % n % n % n % n % n % n % n % n % n % n %
I. Leukemias 54 37.8 321 43.7 43 34.4 431 51.4 54 46.2 97 50.8 56 31.6 56 49.1 60 48.0 25 49.0 1197 45.8 1
+ Acute lymphoblastic 37 68.5 249 77.6 35 81.4 352 81.7 42 77.7 78 80.3 53 94.6 48 85.7 46 76.7 18 72.0 958 80.0 2
+ Acute non-lymphoblastic 16 29.6 58 18.1 7 16.3 70 16.3 12 22.3 16 16.5 3 5.4 8 14.3 11 18.3 5 20.0 206 17.2
II. Lymphomas 3 15 10.5 88 12.0 21 16.8 75 9.0 15 12.9 17 8.9 22 12.4 19 16.7 16 12.8 1 2.0 289 11.1
+ Hodgkin lymphomas 6 40.0 23 25.9 7 33.3 36 47.8 3 20.2 6 34.8 10 45.2 10 52.7 9 56.3 1 100.0 111 38.4
+ Non Hodgkin lymphomas 7 46.7 53 60.4 9 42.9 35 46.7 9 59.7 7 41.6 8 36.3 8 41.9 4 25.0 0 0.0 140 48.4
+ Burkitt lymphoma 2 13.3 9 10.3 5 23.8 3 4.4 3 20.2 4 23.6 3 13.7 1 5.4 3 18.8 0 0.0 33 11.4
III. CNS tumors 21 14.7 98 13.4 23 18.4 75 9.0 11 9.5 20 10.5 33 18.6 10 8.8 19 15.2 5 9.8 315 12.0
+ Ependymomas 3 14.3 14 14.2 3 13.0 10 13.3 1 9.5 1 4.9 2 5.9 0 0.0 4 21.1 0 0.0 38 12.1
+ Astrocytomas 9 42.9 52 53.0 13 56.5 31 41.1 5 45.3 5 24.8 14 42.5 4 39.8 5 26.3 1 20.4 139 44.1
+ IIET 5 23.8 25 25.4 6 26.1 25 33.3 3 27.4 4 20.3 12 36.6 1 10.2 5 26.3 2 39.8 88 27.9
IV. Neuroblastoma and others 3 2.1 22 3.0 8 6.4 16 1.9 2 1.7 4 2.1 11 6.2 1 0.9 1 0.8 3 5.9 71 2.7
+ Neuroblastoma 3 100.0 21 96.7 8 100.0 14 89.5 2 100.0 4 100.0 10 90.3 1 100.0 1 100.0 3 100.0 66 93.0
V. Retinoblastoma 12 8.4 26 3.5 5 4.0 33 3.9 6 5.1 3 1.6 7 4.0 4 3.5 6 4.8 3 5.9 105 4.0
VI. Renal tumors 4 2.8 30 4.1 7 5.6 33 4.0 7 6.0 5 2.6 10 5.6 2 1.8 6 4.8 2 3.9 106 4.1
+ Nephroblastoma 4 100.0 28 97.5 7 100.0 33 100.0 7 100.0 5 100.0 10 100.0 2 100.0 6 100.0 2 100.0 105 99.1
VII. Hepatic tumors 3 2.1 19 2.6 0 0.0 10 1.2 1 0.9 4 2.1 3 1.7 6 5.3 1 0.8 1 2.0 48 1.8
+ Hepatoblastoma 2 66.7 17 88.5 0 0.0 9 91.7 1 100.0 4 100.0 3 100.0 6 100.0 1 100.0 1 100.0 44 91.7
VIII. Bone tumors 10 7.0 39 5.3 8 6.4 47 5.6 7 6.0 20 10.5 5 2.8 5 4.4 3 2.4 4 7.8 148 5.7
+ Osteosarcomas 8 80.0 27 70.0 5 62.5 36 76.8 4 56.7 19 94.9 4 80.0 3 59.1 2 66.7 2 50.0 110 74.3
IX. Soft tissue sarcomas 9 6.3 41 5.6 6 4.8 44 5.3 7 6.0 13 6.8 14 7.9 5 4.4 4 3.2 2 3.9 145 5.5
+ Rhabdomyosarcomas 4 44.4 25 61.2 1 16.7 27 60.4 4 56.7 8 61.8 12 85.4 2 40.9 4 100.0 1 50.0 88 60.7
+ Fibrosarcomas 4 44.4 9 21.9 1 16.7 8 18.9 1 15.0 0 0.0 1 7.3 0 0.0 0 0.0 0 0.0 24 16.6
X. Germ cell tumors 7 4.9 45 6.1 2 1.6 67 8.0 5 4.3 7 3.7 14 7.9 6 5.3 9 7.2 5 9.8 167 6.4
+ Malignant gonadal 4 57.1 35 77.8 2 100.0 49 72.5 2 39.5 3 43.2 10 70.9 4 66.0 4 44.4 4 79.6 117 70.1
XI. Carcinomas 5 3.5 5 0.7 2 1.6 7 0.7 2 1.7 1 0.5 2 1.1 0 0.0 0 0.0 0 0.0 24 0.9
TOTAL 143 100 734 100 125 100 838 100 117 100 191 100 177 100 114 100 125 100 51 100 2615 100
  1. 1Intergroup frequency (%); 2Intragroup frequency (%), only the frequencies of principal subgroups are presented; 363 cases of Histiocytosis were not included; IMSS, Instituto Mexicano del Seguro Social; n, Number of cases; CNS, Central Nervous System; IIET, Intracraneal and Intraespinal Embryonal Tumors; CHIS, Chiapas; MC, Mexico City; GRO, Guerrero; MS, Mexico State; MOR, Morelos; JAL, Jalisco; NL, Nuevo León; PUE, Puebla; VER, Veracurz; YUC, Yucatán.